1887

Abstract

Human adenoviruses have been the subject of intensive investigation since their discovery in the early 1950s: they have served as model pathogens, as probes for studying cellular processes and, more recently, as efficient gene-delivery vehicles for experimental gene therapy. As a result, a detailed insight into many aspects of adenovirus biology is now available. The capsid proteins and in particular the hexon, penton-base and fibre proteins (the so-called major capsid proteins) have been studied extensively and their structure and function in the virus capsid are now well-defined. On the other hand, the minor proteins in the viral capsid, i.e. proteins IIIa, VI, VIII and IX, have received much less attention. Only the last few years have witnessed a sharp increase in the number of studies on their structure and function. Here, a review of the minor capsid proteins is provided, with a focus on new insights into their position and role in the capsid and the opportunities that they provide for improving human adenovirus-derived gene-delivery vectors.

Loading

Article metrics loading...

/content/journal/jgv/10.1099/vir.0.80877-0
2005-06-01
2019-09-22
Loading full text...

Full text loading...

/deliver/fulltext/jgv/86/6/vir861581.html?itemId=/content/journal/jgv/10.1099/vir.0.80877-0&mimeType=html&fmt=ahah

References

  1. Akalu, A., Liebermann, H., Bauer, U., Granzow, H. & Seidel, W. ( 1999; ). The subgenus-specific C-terminal region of protein IX is located on the surface of the adenovirus capsid. J Virol 73, 6182–6187.
    [Google Scholar]
  2. Barnett, B. G., Crews, C. J. & Douglas, J. T. ( 2002; ). Targeted adenoviral vectors. Biochim Biophys Acta 1575, 1–14.[CrossRef]
    [Google Scholar]
  3. Barouch, D. H., Pau, M. G., Custers, J. H. H. V. & 15 other authors ( 2004; ). Immunogenicity of recombinant adenovirus serotype 35 vaccine in the presence of pre-existing anti-Ad5 immunity. J Immunol 172, 6290–6297.[CrossRef]
    [Google Scholar]
  4. Belousova, N., Krendelchtchikova, V., Curiel, D. T. & Krasnykh, V. ( 2002; ). Modulation of adenovirus vector tropism via incorporation of polypeptide ligands into the fiber protein. J Virol 76, 8621–8631.[CrossRef]
    [Google Scholar]
  5. Benkő, M. & Harrach, B. ( 2003; ). Molecular evolution of adenoviruses. Curr Top Microbiol Immunol 272, 3–35.
    [Google Scholar]
  6. Boudin, M.-L., D'Halluin, J.-C., Cousin, C. & Boulanger, P. ( 1980; ). Human adenovirus type 2 protein IIIa. II. Maturation and encapsidation. Virology 101, 144–156.[CrossRef]
    [Google Scholar]
  7. Boulanger, P., Lemay, P., Blair, G. E. & Russell, W. C. ( 1979; ). Characterization of adenovirus protein IX. J Gen Virol 44, 783–800.[CrossRef]
    [Google Scholar]
  8. Campos, S. K., Parrott, M. B. & Barry, M. A. ( 2004a; ). Avidin-based targeting and purification of a protein IX-modified, metabolically biotinylated adenoviral vector. Mol Ther 9, 942–954.[CrossRef]
    [Google Scholar]
  9. Campos, S. K., Parrott, M. B., March, M., Chiu, W. & Barry, M. A. ( 2004b; ). Metabolically biotinylated viruses for vector targeting, virus purification, and capsid imaging. Mol Ther 9 (Suppl. 1), S390.
    [Google Scholar]
  10. Chatterjee, P. K., Vayda, M. E. & Flint, S. J. ( 1985; ). Interactions among the three adenovirus core proteins. J Virol 55, 379–386.
    [Google Scholar]
  11. Chroboczek, J., Viard, F. & D'Halluin, J.-C. ( 1986; ). Human adenovirus 2 temperature-sensitive mutant 112 contains three mutations in the protein IIIa gene. Gene 49, 157–160.[CrossRef]
    [Google Scholar]
  12. Colby, W. W. & Shenk, T. ( 1981; ). Adenovirus type 5 virions can be assembled in vivo in the absence of detectable polypeptide IX. J Virol 39, 977–980.
    [Google Scholar]
  13. Crompton, J., Toogood, C. I. A., Wallis, N. & Hay, R. T. ( 1994; ). Expression of a foreign epitope on the surface of the adenovirus hexon. J Gen Virol 75, 133–139.[CrossRef]
    [Google Scholar]
  14. Curiel, D. T. ( 2002; ). Strategies to alter the tropism of adenoviral vectors via genetic capsid modification. In Vector Targeting for Therapeutic Gene Delivery, pp. 171–200. Edited by D. T. Curiel & J. T. Douglas. Hoboken, NJ, USA: Wiley-Liss.
  15. Curiel, D. T. ( 2003; ). Capsid-modified recombinant adenovirus and methods of use. United States patent 6555368.
  16. Davison, A. J., Benkő, M. & Harrach, B. ( 2003; ). Genetic content and evolution of adenoviruses. J Gen Virol 84, 2895–2908.[CrossRef]
    [Google Scholar]
  17. De Jong, J. C., Wermenbol, A. G., Verweij-Uijterwaal, M. W., Slaterus, K. W., Wertheim-Van Dillen, P., Van Doornum, G. J. J., Khoo, S. H. & Hierholzer, J. C. ( 1999; ). Adenoviruses from human immunodeficiency virus-infected individuals, including two strains that represent new candidate serotypes Ad50 and Ad51 of species B1 and D, respectively. J Clin Microbiol 37, 3940–3945.
    [Google Scholar]
  18. D'Halluin, J. C., Cousin, C. & Boulanger, P. ( 1982; ). Physical mapping of adenovirus type 2 temperature-sensitive mutations by restriction endonuclease analysis of interserotypic recombinants. J Virol 41, 401–413.
    [Google Scholar]
  19. Dmitriev, I. P., Kashentseva, E. A. & Curiel, D. T. ( 2002; ). Engineering of adenovirus vectors containing heterologous peptide sequences in the C terminus of capsid protein IX. J Virol 76, 6893–6899.[CrossRef]
    [Google Scholar]
  20. Einfeld, D. A., Brough, D. E., Roelvink, P. W., Kovesdi, I. & Wickham, T. J. ( 1999; ). Construction of a pseudoreceptor that mediates transduction by adenoviruses expressing a ligand in fiber or penton base. J Virol 73, 9130–9136.
    [Google Scholar]
  21. Everitt, E. & Philipson, L. ( 1974; ). Structural proteins of adenoviruses. XI. Purification of three low molecular weight virion proteins of adenovirus type 2 and their synthesis during productive infection. Virology 62, 253–269.[CrossRef]
    [Google Scholar]
  22. Everitt, E., Sundquist, B., Pettersson, U. & Philipson, L. ( 1973; ). Structural proteins of adenoviruses. X. Isolation and topography of low molecular weight antigens from the virion of adenovirus type 2. Virology 52, 130–147.[CrossRef]
    [Google Scholar]
  23. Everitt, E., Lutter, L. & Philipson, L. ( 1975; ). Structural proteins of adenoviruses. XII. Location and neighbor relationship among proteins of adenovirion type 2 as revealed by enzymatic iodination, immunoprecipitation and chemical cross-linking. Virology 67, 197–208.[CrossRef]
    [Google Scholar]
  24. Furcinitti, P. S., van Oostrum, J. & Burnett, R. M. ( 1989; ). Adenovirus polypeptide IX revealed as capsid cement by difference images from electron microscopy and crystallography. EMBO J 8, 3563–3570.
    [Google Scholar]
  25. Gall, J., Kass-Eisler, A., Leinwand, L. & Falck-Pedersen, E. ( 1996; ). Adenovirus type 5 and 7 capsid chimera: fiber replacement alters receptor tropism without affecting primary immune neutralization epitopes. J Virol 70, 2116–2123.
    [Google Scholar]
  26. Ghosh-Choudhury, G., Haj-Ahmad, Y. & Graham, F. L. ( 1987; ). Protein IX, a minor component of the human adenovirus capsid, is essential for the packaging of full length genomes. EMBO J 6, 1733–1739.
    [Google Scholar]
  27. Greber, U. F., Willetts, M., Webster, P. & Helenius, A. ( 1993; ). Stepwise dismantling of adenovirus 2 during entry into cells. Cell 75, 477–486.[CrossRef]
    [Google Scholar]
  28. Havenga, M. J. E., Lemckert, A. A. C., Ophorst, O. J. A. E. & 13 other authors ( 2002; ). Exploiting the natural diversity in adenovirus tropism for therapy and prevention of disease. J Virol 76, 4612–4620.[CrossRef]
    [Google Scholar]
  29. Henning, P., Magnusson, M. K., Gunneriusson, E., Hong, S. S., Boulanger, P., Nygren, P.-Å. & Lindholm, L. ( 2002; ). Genetic modification of adenovirus 5 tropism by a novel class of ligands based on a three-helix bundle scaffold derived from staphylococcal protein A. Hum Gene Ther 13, 1427–1439.[CrossRef]
    [Google Scholar]
  30. Holterman, L., Vogels, R., van der Vlugt, R. & 15 other authors ( 2004; ). Novel replication-incompetent vector derived from adenovirus type 11 (Ad11) for vaccination and gene therapy: low seroprevalence and non-cross-reactivity with Ad5. J Virol 78, 13207–13215.[CrossRef]
    [Google Scholar]
  31. Huvent, I., Hong, S. S., Fournier, C. & 7 other authors ( 1998; ). Interaction and co-encapsidation of human immunodeficiency virus type 1 Gag and Vif recombinant proteins. J Gen Virol 79, 1069–1081.
    [Google Scholar]
  32. Krasnykh, V. N., Mikheeva, G. V., Douglas, J. T. & Curiel, D. T. ( 1996; ). Generation of recombinant adenovirus vectors with modified fibers for altering viral tropism. J Virol 70, 6839–6846.
    [Google Scholar]
  33. Krasnykh, V., Belousova, N., Korokhov, N., Mikheeva, G. & Curiel, D. T. ( 2001; ). Genetic targeting of an adenovirus vector via replacement of the fiber protein with the phage T4 fibritin. J Virol 75, 4176–4183.[CrossRef]
    [Google Scholar]
  34. Le, L. P., Everts, M., Dmitriev, I. P., Davydova, J. G., Yamamoto, M. & Curiel, D. T. ( 2004; ). Fluorescently labeled adenovirus with pIX-EGFP for vector detection. Mol Imaging 3, 105–116.[CrossRef]
    [Google Scholar]
  35. Liu, G.-Q., Babiss, L. E., Volkert, F. C., Young, C. S. H. & Ginsberg, H. S. ( 1985; ). A thermolabile mutant of adenovirus 5 resulting from a substitution mutation in the protein VIII gene. J Virol 53, 920–925.
    [Google Scholar]
  36. Lutz, P., Rosa-Calatrava, M. & Kedinger, C. ( 1997; ). The product of the adenovirus intermediate gene IX is a transcriptional activator. J Virol 71, 5102–5109.
    [Google Scholar]
  37. Magnusson, M. K., Hong, S. S., Henning, P., Boulanger, P. & Lindholm, L. ( 2002; ). Genetic retargeting of adenovirus vectors: functionality of targeting ligands and their influence on virus viability. J Gene Med 4, 356–370.[CrossRef]
    [Google Scholar]
  38. Mangel, W. F., McGrath, W. J., Toledo, D. L. & Anderson, C. W. ( 1993; ). Viral DNA and a viral peptide can act as cofactors of adenovirus virion proteinase activity. Nature 361, 274–275.[CrossRef]
    [Google Scholar]
  39. Matthews, D. A. & Russell, W. C. ( 1995; ). Adenovirus protein–protein interactions: molecular parameters governing the binding of protein VI to hexon and the activation of the adenovirus 23K protease. J Gen Virol 76, 1959–1969.[CrossRef]
    [Google Scholar]
  40. Meulenbroek, R. A., Sargent, K. L., Lunde, J., Jasmin, B. J. & Parks, R. J. ( 2004; ). Use of adenovirus protein IX (pIX) to display large polypeptides on the virion – generation of fluorescent virus through the incorporation of pIX-GFP. Mol Ther 9, 617–624.[CrossRef]
    [Google Scholar]
  41. Michael, S. I., Hong, J. S., Curiel, D. T. & Engler, J. A. ( 1995; ). Addition of a short peptide ligand to the adenovirus fiber protein. Gene Ther 2, 660–668.
    [Google Scholar]
  42. Mizuguchi, H. & Hayakawa, T. ( 2004; ). Targeted adenovirus vectors. Hum Gene Ther 15, 1034–1044.[CrossRef]
    [Google Scholar]
  43. Mizuguchi, H., Koizumi, N., Hosono, T., Utoguchi, N., Watanabe, Y., Kay, M. A. & Hayakawa, T. ( 2001; ). A simplified system for constructing recombinant adenoviral vectors containing heterologous peptides in the HI loop of their fiber knob. Gene Ther 8, 730–735.[CrossRef]
    [Google Scholar]
  44. Molin, M., Bouakaz, L., Berenjian, S. & Akusjärvi, G. ( 2002; ). Unscheduled expression of capsid protein IIIa results in defects in adenovirus major late mRNA and protein expression. Virus Res 83, 197–206.[CrossRef]
    [Google Scholar]
  45. Newcomb, W. W. & Brown, J. C. ( 1988; ). Use of Ar+ plasma etching to localize structural proteins in viruses: studies with adenovirus 2. Anal Biochem 169, 279–286.[CrossRef]
    [Google Scholar]
  46. Pacini, D. L., Dubovi, E. J. & Clyde, W. A., Jr ( 1984; ). A new animal model for human respiratory tract disease due to adenovirus. J Infect Dis 150, 92–97.[CrossRef]
    [Google Scholar]
  47. Rosa-Calatrava, M., Grave, L., Puvion-Dutilleul, F., Chatton, B. & Kedinger, C. ( 2001; ). Functional analysis of adenovirus protein IX identifies domains involved in capsid stability, transcriptional activity, and nuclear reorganization. J Virol 75, 7131–7141.[CrossRef]
    [Google Scholar]
  48. Rosa-Calatrava, M., Puvion-Dutilleul, F., Lutz, P., Dreyer, D., de Thé, H., Chatton, B. & Kedinger, C. ( 2003; ). Adenovirus protein IX sequesters host-cell promyelocytic leukaemia protein and contributes to efficient viral proliferation. EMBO Rep 4, 969–975.[CrossRef]
    [Google Scholar]
  49. Russell, W. C. ( 2000; ). Update on adenovirus and its vectors. J Gen Virol 81, 2573–2604.
    [Google Scholar]
  50. Rux, J. J. & Burnett, R. M. ( 2000; ). Type-specific epitope locations revealed by X-ray crystallographic study of adenovirus type 5 hexon. Mol Ther 1, 18–30.[CrossRef]
    [Google Scholar]
  51. Rux, J. J., Kuser, P. R. & Burnett, R. M. ( 2003; ). Structural and phylogenetic analysis of adenovirus hexons by use of high-resolution X-ray crystallographic, molecular modeling, and sequence-based methods. J Virol 77, 9553–9566.[CrossRef]
    [Google Scholar]
  52. San Martín, C. & Burnett, R. M. ( 2003; ). Structural studies on adenoviruses. Curr Top Microbiol Immunol 272, 57–94.
    [Google Scholar]
  53. Sargent, K. L., Meulenbroek, R. A. & Parks, R. J. ( 2004a; ). Activation of adenoviral gene expression by protein IX is not required for efficient virus replication. J Virol 78, 5032–5037.[CrossRef]
    [Google Scholar]
  54. Sargent, K. L., Ng, P., Evelegh, C., Graham, F. L. & Parks, R. J. ( 2004b; ). Development of a size-restricted pIX-deleted helper virus for amplification of helper-dependent adenovirus vectors. Gene Ther 11, 504–511.[CrossRef]
    [Google Scholar]
  55. Souquere-Besse, S., Pichard, E., Filhol, O., Legrand, V., Rosa-Calatrava, M., Hovanessian, A. G., Cochet, C. & Puvion-Dutilleul, F. ( 2002; ). Adenovirus infection targets the cellular protein kinase CK2 and RNA-activated protein kinase (PKR) into viral inclusions of the cell nucleus. Microsc Res Tech 56, 465–478.[CrossRef]
    [Google Scholar]
  56. Stevenson, S. C., Rollence, M., White, B., Weaver, L. & McClelland, A. ( 1995; ). Human adenovirus serotypes 3 and 5 bind to two different cellular receptors via the fiber head domain. J Virol 69, 2850–2857.
    [Google Scholar]
  57. Stewart, P. L., Burnett, R. M., Cyrklaff, M. & Fuller, S. D. ( 1991; ). Image reconstruction reveals the complex molecular organization of adenovirus. Cell 67, 145–154.[CrossRef]
    [Google Scholar]
  58. Stewart, P. L., Fuller, S. D. & Burnett, R. M. ( 1993; ). Difference imaging of adenovirus: bridging the resolution gap between X-ray crystallography and electron microscopy. EMBO J 12, 2589–2599.
    [Google Scholar]
  59. Tsuzuki, J. & Luftig, R. B. ( 1983; ). The adenovirus type 5 capsid protein IIIa is phosphorylated during an early stage of infection of HeLa cells. Virology 129, 529–533.[CrossRef]
    [Google Scholar]
  60. Tsuzuki, J. & Luftig, R. B. ( 1985; ). Evidence for the ubiquitous presence of a protein kinase in human adenoviruses capable of preferentially phosphorylating capsid protein IIIa. Intervirology 23, 90–96.[CrossRef]
    [Google Scholar]
  61. Uil, T. G., Seki, T., Dmitriev, I., Kashentseva, E., Douglas, J. T., Rots, M. G., Middeldorp, J. M. & Curiel, D. T. ( 2003; ). Generation of an adenoviral vector containing an addition of a heterologous ligand to the serotype 3 fiber knob. Cancer Gene Ther 10, 121–124.[CrossRef]
    [Google Scholar]
  62. van Beusechem, V. W., van Rijswijk, A. L. C. T., van Es, H. H. G., Haisma, H. J., Pinedo, H. M. & Gerritsen, W. R. ( 2000; ). Recombinant adenovirus vectors with knobless fibers for targeted gene transfer. Gene Ther 7, 1940–1946.[CrossRef]
    [Google Scholar]
  63. van Oostrum, J. & Burnett, R. M. ( 1985; ). Molecular composition of the adenovirus type 2 virion. J Virol 56, 439–448.
    [Google Scholar]
  64. Vellekamp, G., Porter, F. W., Sutjipto, S. & 9 other authors ( 2001; ). Empty capsids in column-purified recombinant adenovirus preparations. Hum Gene Ther 12, 1923–1936.[CrossRef]
    [Google Scholar]
  65. Vellinga, J., Rabelink, M. J. W. E., Cramer, S. J., van den Wollenberg, D. J. M., Van der Meulen, H., Leppard, K. N., Fallaux, F. J. & Hoeben, R. C. ( 2004; ). Spacers increase the accessibility of peptide ligands linked to the carboxyl terminus of adenovirus minor capsid protein IX. J Virol 78, 3470–3479.[CrossRef]
    [Google Scholar]
  66. Vellinga, J., van den Wollenberg, D. J. M., van der Heijdt, S., Rabelink, M. J. W. E. & Hoeben, R. C. ( 2005; ). The coiled-coil domain of the adenovirus type 5 protein IX is dispensable for capsid incorporation and thermostability. J Virol 79, 3206–3210.[CrossRef]
    [Google Scholar]
  67. Vigne, E., Mahfouz, I., Dedieu, J.-F., Brie, A., Perricaudet, M. & Yeh, P. ( 1999; ). RGD inclusion in the hexon monomer provides adenovirus type 5-based vectors with a fiber knob-independent pathway for infection. J Virol 73, 5156–5161.
    [Google Scholar]
  68. Vogels, R., Zuijdgeest, D., van Rijnsoever, R. & 20 other authors ( 2003; ). Replication-deficient human adenovirus type 35 vectors for gene transfer and vaccination: efficient human cell infection and bypass of preexisting adenovirus immunity. J Virol 77, 8263–8271.[CrossRef]
    [Google Scholar]
  69. Webster, A., Hay, R. T. & Kemp, G. ( 1993; ). The adenovirus protease is activated by a virus-coded disulphide-linked peptide. Cell 72, 97–104.[CrossRef]
    [Google Scholar]
  70. Wickham, T. J., Roelvink, P. W., Brough, D. E. & Kovesdi, I. ( 1996; ). Adenovirus targeted to heparan-containing receptors increases its gene delivery efficiency to multiple cell types. Nat Biotechnol 14, 1570–1573.[CrossRef]
    [Google Scholar]
  71. Wiethoff, C. M., Wodrich, H., Gerace, L. & Nemerow, G. R. ( 2005; ). Adenovirus protein VI mediates membrane disruption following capsid disassembly. J Virol 79, 1992–2000.[CrossRef]
    [Google Scholar]
  72. Wodrich, H., Guan, T., Cingolani, G., Von Seggern, D., Nemerow, G. & Gerace, L. ( 2003; ). Switch from capsid protein import to adenovirus assembly by cleavage of nuclear transport signals. EMBO J 22, 6245–6255.[CrossRef]
    [Google Scholar]
  73. Wu, H., Han, T., Belousova, N., Krasnykh, V., Kashentseva, E., Dmitriev, I., Kataram, M., Mahasreshti, P. J. & Curiel, D. T. ( 2005; ). Identification of sites in adenovirus hexon for foreign peptide incorporation. J Virol 79, 3382–3390.[CrossRef]
    [Google Scholar]
http://instance.metastore.ingenta.com/content/journal/jgv/10.1099/vir.0.80877-0
Loading
/content/journal/jgv/10.1099/vir.0.80877-0
Loading

Data & Media loading...

Most Cited This Month

This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error